Azitra (NYSEAMERICAN:AZTR) Announces Quarterly Earnings Results

Azitra (NYSEAMERICAN:AZTR) posted its earnings results on Tuesday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.31, Zacks reports.

Azitra Stock Down 12.0 %

AZTR traded down $0.06 during trading on Thursday, hitting $0.43. The company had a trading volume of 118,174 shares, compared to its average volume of 888,130. Azitra has a one year low of $0.43 and a one year high of $68.40. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.01.

Azitra Company Profile

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.